Stryker Corporation (SYK) 2024 10-K Earnings Analysis
Stryker Corporation2024 Earnings Analysis
80/100
Stryker's FY2024 is a procedure-and-platform story: $22.6B revenue, $3.0B net income, $3.5B free cash flow, and a 63.9% gross margin profile built around Orthopaedics, MedSurg, and Neurotechnology. What makes the economics distinctive is the combination of Mako pull-through, hospital workflow entrenchment, and a steady tuck-in acquisition cadence. The issue is not whether Stryker can grow; it is whether acquisition-heavy expansion can keep compounding without pushing goodwill concentration too far.
Filing analysis
Stryker Corporation 2024 10-K Analysis
This page reads Stryker Corporation's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 80/100, or grade B.
SYK Earnings Quality
The earnings-quality module scores 82/100, with Gross Margin: 63.9%, CF/Net Income: 1.42x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
SYK Economic Moat Analysis
The moat-strength module scores 85/100, with Mako Robotic Platform: Orthopaedic robotic leadership, Hospital Relationships: Multi-department. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
SYK Free Cash Flow vs Net Income
CF/Net Income: 1.42x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 82/100. For the diagnostic, start with cash flow vs net income.
SYK Key Risks from the Annual Report
The risk module scores 72/100, with Hospital Capex: Cycle-linked, Goodwill Concentration: 36.9%. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is SYK a High Quality Earnings Stock?
Based on this 2024 filing, SYK passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 82/100. This is a research screen, not investment advice.
Read the report first
Understand Stryker Corporation first, then decide if it belongs on your watchlist
The SYK score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep SYK with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the SYK report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 63.9% reflects the medical-device cost structure across hips/knees implants, surgical instruments, hospital capital equipment, and neurovascular products disclosed in the segment footnote.
Per the FY2024 cash flow statement, OCF of $4.2B is 1.42x net income of $3.0B — the spread driven by acquisition-intangible amortization from the M&A portfolio (Wright Medical, Vocera, Mako, Inari Medical per the respective closing press releases).
Per the FY2024 10-K income statement, operating margin of 16.3% reflects the current-period mix across Orthopaedics (Mako robotic-assisted surgery, hips/knees, trauma), MedSurg (Sage patient-care products, endoscopy, instruments, medical beds), and Neurotechnology (neurovascular including the 2024 Inari-acquired venous-thromboembolism devices).
Per the FY2024 segment disclosures, Stryker reports in Orthopaedics, MedSurg, and Neurotechnology. MedSurg has been expanded via the Vocera (2022 clinical communications) acquisition; Neurotechnology expanded via the 2024 Inari Medical closing per the respective press releases.
Earnings quality scores 82/100. Per the FY2024 10-K, Stryker's $22.6B revenue produces a 63.9% gross margin and 1.42x CF/NI ratio — the profile of a scaled medical-device operator with sustained M&A-driven intangible amortization. The three-segment structure (Orthopaedics including Mako robotic-assisted surgery, MedSurg, Neurotechnology) diversifies across the surgical-and-hospital medical-device value chain.
Moat Strength
Per the FY2024 Orthopaedics segment MD&A, the Mako robotic-arm-assisted surgery platform (acquired via the Mako Surgical acquisition in 2013 per the closing press release) has grown its installed base across hip, knee, and shoulder procedures. The platform drives pull-through of Stryker implants (Triathlon knee, Restoris hip).
Per the FY2024 10-K MedSurg and Neurotechnology segment disclosures, Stryker sells across orthopaedic surgery, general surgery, endoscopy, neurosurgery, and critical care — broad hospital-department relationships compounded through combined sales organizations. Customer concentration across hospital systems is disclosed in the customer-concentration section.
Per the FY2024 Orthopaedics segment disclosures, Stryker's implant portfolio includes Triathlon knee, Restoris hip, Tornier shoulder (from Wright Medical acquisition), and Mako robotic-compatible implant lines. Multi-product portfolio depth supports surgeon-preference capture.
Goodwill of $16B on $43B assets equals 36.9% per the FY2024 balance sheet — reflecting multi-year M&A including Wright Medical ($5.4B 2020 per the closing press release), Vocera ($3.1B 2022), Mako Surgical ($1.7B 2013), and Inari Medical (~$4.9B 2024).
Moat strength scores 85/100. Stryker's moat is built around the operating room rather than around a single product label. Mako ties implants to procedure workflow, MedSurg broadens the hospital relationship beyond orthopaedics, and Neurotechnology plus Inari extend the company into adjacent interventional categories. That creates a hospital-system relationship that is wider than a pure implant franchise and more procedure-dependent than Abbott's diversified healthcare model.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $3.5B (OCF $4.2B minus capex $0.76B) supports the dividend, share repurchase, and M&A disclosed in the capital-allocation section.
Per the FY2024 dividend-history disclosure, Stryker has raised its dividend for more than 30 consecutive years — qualifying for Dividend Aristocrat designation per the S&P index-membership criteria published in financial-media indexes.
Per Stryker's 2024 Inari Medical closing press release, the approximately $4.9B all-cash transaction added ClotTriever and FlowTriever venous-thromboembolism-removal devices to the Neurotechnology segment. Integration progress is disclosed in quarterly investor updates.
$0.76B capex on $22.6B revenue equals 3.4% capital intensity — disciplined for a medical-device manufacturer; the capex profile funds manufacturing-capacity expansion and Mako-platform production referenced in MD&A.
Capital allocation scores 82/100. Stryker's capital allocation keeps rotating around the same pattern: fund internal manufacturing and platform capacity, protect the dividend, and then use M&A to deepen either workflow or specialty exposure. That makes the file look very different from a cash-harvest medtech. The open question is whether future deals keep reinforcing Mako and hospital breadth, or simply add more balance-sheet weight.
Key Risks
Per the FY2024 Risk Factors, hospital-capital-equipment orders (Mako systems, beds, stretchers) track hospital capital-budget cycles. Hospital-financial-pressure periods compress capital-equipment placement cadence.
Per the FY2024 balance sheet, $16B goodwill concentrates impairment risk on the reporting units carrying the largest allocated purchase-price allocations (Wright Medical, Vocera, Inari, Mako). Impairment testing follows the disclosed policy.
Per the FY2024 Risk Factors, Mako competes with Intuitive Surgical's da Vinci in select orthopaedic and general-surgery overlap areas (though the primary competitive overlap is in orthopaedics) and with Medtronic's Mazor-X plus Hugo RAS platforms per the publicly-announced product launches.
Per the FY2024 Risk Factors, the orthopaedic-implant category has faced multi-year disclosed pricing pressure from group-purchasing-organizations (GPOs), Medicare reimbursement rate changes, and international-market price controls. Offset through Mako pull-through and product-mix upgrades.
Risk profile scores 72/100 (higher = safer). Per the FY2024 10-K, the main watch-items are (1) hospital-capital-budget cycle sensitivity for Mako and other capital-equipment placements, (2) the 36.9% goodwill concentration from the multi-year M&A cadence, (3) robotic-platform competition from Intuitive Surgical da Vinci and Medtronic Mazor-X/Hugo RAS, and (4) orthopaedic-implant pricing pressure disclosed via GPO contracts and Medicare reimbursement rules.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.